MOTS-c Clinical Trial: What Human Research Actually Shows

As of today, no FDA-approved MOTS-c clinical trial exists for human use, and MOTS-c itself has never been tested in a published randomized human study. The only human data tied to this peptide comes from an early-phase program testing CB4211, a synthetic MOTS-c analog, which was discontinued before larger trials could be completed. Most of what circulates online about MOTS-c — better insulin sensitivity, exercise-like metabolic effects, fat loss — comes from mice and cell cultures, not from people.

What MOTS-c Actually Is

MOTS-c is a 16-amino-acid peptide encoded in the mitochondrial genome, specifically within the 12S ribosomal RNA region. It was described in 2015 by researchers at the University of Southern California and is usually grouped with other mitochondrial-derived peptides.

Inside the body, MOTS-c travels from mitochondria to the nucleus under metabolic stress and helps regulate the folate-methionine cycle and AMPK signaling. Plasma levels of MOTS-c tend to decline with age and track with insulin sensitivity in observational studies, which is why the peptide attracts so much attention in longevity and metabolic research.

What MOTS-c is not: an approved drug, a vitamin, or a dietary supplement. MOTS-c sold online is labeled for research use only and is not intended for human consumption.

MOTS-c Clinical Trial Data in Humans

If you are looking for mots c human trials, the honest answer is that only one modified version of the peptide has ever reached people, in a small study that stopped early.

The closest thing to a MOTS-c human trial is the CB4211 program run by CohBar, a biotech company that has since shut down. CB4211 is a modified MOTS-c analog designed to last longer in the body than the natural peptide.

• Phase 1a: single and multiple ascending subcutaneous doses in healthy volunteers, designed to check safety and pharmacokinetics.
• Phase 1b: a short, placebo-controlled study in adults with obesity and nonalcoholic steatohepatitis (NASH), looking at tolerability and early signals of liver fat reduction.
• Reported results: the company described the drug as generally well tolerated with no serious adverse events and reported trends toward lower liver fat and body weight in a small number of participants.
• Status: the program was discontinued before Phase 2, and detailed peer-reviewed results were never published in full.

Program	Phase	Population	Route	Reported outcome	Status
CB4211 (MOTS-c analog)	Phase 1a	Healthy adults	Subcutaneous	Generally well tolerated; no serious adverse events reported	Completed
CB4211 (MOTS-c analog)	Phase 1b	Adults with obesity and NASH	Subcutaneous	Early signals of reduced liver fat and weight; very small sample	Discontinued
MOTS-c (native peptide)	None	No human participants	Not applicable	No published human efficacy data	Preclinical only

Two conclusions matter here. No completed, peer-reviewed, placebo-controlled human trial of MOTS-c itself has ever been published. A discontinued Phase 1 program is not evidence that a peptide works — it is evidence that it was tolerated well enough to keep studying, and then the research stopped.

Why Human MOTS-c Research Is So Hard to Run

Several practical problems stand between MOTS-c and a large human trial.

• Short half-life. Native MOTS-c breaks down quickly, so any drug version has to be chemically modified, which means the molecule studied is no longer identical to the natural peptide.
• Delivery. MOTS-c is not orally bioavailable and would require injection.
• Funding. Metabolic trials are expensive, and there is no patent on the natural peptide to pay for them.
• Endpoints. Improved metabolism is not a measurable endpoint; a real trial needs defined markers such as HbA1c, HOMA-IR, or liver fat measured by MRI.

Researchers often compare this problem to other mitochondrial peptides. The elamipretide clinical trial program is a useful benchmark because it is one of the few mitochondrial-targeted peptides to reach late-stage human testing, and even it has had a mixed record with regulators. The earlier ss-31 clinical trial work behind elamipretide shows how many years and how much money it takes to move from mouse data to human data.

How MOTS-c Compares With Other Peptides People Search For

Interest in MOTS-c rarely stands alone, and it helps to see where the peptide sits relative to better-studied compounds.

Compound	Main research focus	Human data	Regulatory status in the US
MOTS-c	Metabolic regulation, AMPK, aging	Analog only (Phase 1, discontinued)	Not approved; sold as a research chemical
Elamipretide (SS-31)	Mitochondrial function, rare disease	Multiple trials, mixed results	Not approved
AOD-9604	Fat metabolism	Small, older obesity studies	Not approved
Tesamorelin	Visceral fat, growth hormone axis	Randomized trials	FDA-approved for HIV-related lipodystrophy
Cagrilintide	Weight management (amylin analog)	Phase 3 program ongoing	Investigational

People frequently look up aod 9604 vs mots-c because both are marketed for fat loss, yet neither has an approved human indication. Questions about stacking the two are not answered by any clinical evidence, because that combination has never been studied in humans.

The cagrilintide clinical trials and the reta peptide clinical trial programs show the standard that metabolic compounds are now held to: thousands of participants, prespecified endpoints, and years of follow-up.

Safety, Legal Status, and Questions for a Clinician

MOTS-c is not approved by the FDA for any human use, and products sold online are not manufactured under pharmaceutical standards. Independent testing has repeatedly found that research-grade peptides can be underdosed, mislabeled, or contaminated.

Athletes should also know that MOTS-c appears on the World Anti-Doping Agency prohibited list, so using it can lead to a suspension even if it does nothing for performance.

Before considering any research peptide, it is worth asking a healthcare professional direct questions:

1. Is there any human evidence that this peptide does what it claims?
2. What are the known risks, including injection-site reactions and immune responses?
3. What is the legal status where I live, and what are the consequences for my sport or my job?

The Bottom Line on MOTS-c Human Trials

MOTS-c is a genuinely interesting mitochondrial peptide with strong preclinical data, but its human story is one discontinued Phase 1 analog program. That is not enough to support dosing protocols, stacking guides, or confident claims about fat loss and longevity.

If a real MOTS-c human trial launches, ClinicalTrials.gov will list it first, with the sponsor, phase, dose, and endpoints in plain view. Until then, treat MOTS-c as an early-stage research compound rather than a proven therapy.

COMMON QUESTIONS

Frequently Asked Questions

Has MOTS-c been tested in humans?

No published randomized trial has tested MOTS-c itself in people. The only human exposure data comes from CB4211, a modified MOTS-c analog that completed a Phase 1a safety study in healthy volunteers and a short Phase 1b study in adults with obesity and NASH. That program was discontinued before Phase 2, so effectiveness in humans remains unproven.

Is MOTS-c FDA approved?

No. MOTS-c is not FDA-approved for any indication, and there is no approved prescription product containing it. What is sold online is labeled for research use only and is not manufactured to pharmaceutical standards. It also appears on the World Anti-Doping Agency prohibited list.

Are there any MOTS-c human trials recruiting right now?

As of now, no recruiting MOTS-c trial for human use is listed in the United States. The Phase 1 program for the analog CB4211 ended when its developer shut down. Anyone tracking legitimate studies can monitor ClinicalTrials.gov for new listings under mitochondrial-derived peptides.